All In Biotech

Drug Trial Radar · NCT06718998

A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity

Evaluation of Different Dose Escalation Regimens for NNC0519-0130 in Participants With Overweight and Obesity

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

134

Actual

Start

Nov 20, 2024

Primary completion

Jan 12, 2026

Study completion Jan 12, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Dec 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Novo Nordisk is developing a new study medicine NNC0519-0130 to improve the treatment options for people living with type 2 diabetes and people with excess body weight. This study will look at the safety and tolerability of NNC0519-0130. The purpose of this study is to investigate if different ways of increasing the dose of NNC0519-0130 in the main and extension phase can lessen the side effects that may occur when people take NNC0519-0130. There will be four different ways of increasing the dose of the study medicine and participants will get assigned to one of these - which one the participants get is decided by chance. This study will last for about 24 weeks.

Conditions

  • Obesity

Interventions

  • NNC0519-0130Drug

    Participants will receive once-weekly or twice weekly NNC0519-0130 subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events (AEs)Time frame: From randomisation (week 0) to week 18

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical University of Graz

    Graz, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.